Cinfa Biotech GmbH

Cinfa Biotech receives positive CHMP opinion for Pelmeg(R) (pegfilgrastim), a proposed biosimilar to Neulasta(R)

Cinfa Biotech begins US partnering and prepares US development for B12019, a proposed biosimilar to Neulasta(R) (pegfilgrastim)

Cinfa Biotech presents additional clinical data for pegfilgrastim biosimilar candidate B12019 at the 59th ASH Annual Meeting

Cinfa Biotech, S.L.: European Medicines Agency accepts Marketing Authorisation Application for Cinfa Biotech’s pegfilgrastim biosimilar B12019 for review

Cinfa Biotech reports clinical development data for pegfilgrastim biosimilar candidate B12019 at the ESMO Congress 2017

Cinfa Biotech announces positive top-line data from second clinical study with pegfilgrastim biosimilar candidate B12019

Cinfa Biotech publishes clinical data abstract at the 58th American Society of Hematology (ASH) Annual Meeting 2016

Cinfa Biotech starts second clinical study of pegfilgrastim biosimilar candidate B12019

Cinfa Biotech announces positive top-line clinical data of pegfilgrastim biosimilar candidate B12019

Cinfa Biotech to participate at four upcoming European and international conferences

Cinfa Biotech to share its experience on the development of biosimilars at three upcoming conferences

Cinfa Biotech to present at two upcoming biosimilar conferences to discuss clinical development strategies

Cinfa Biotech treats first subjects in pegfilgrastim biosimilar clinical trial

Cinfa Biotech initiates biosimilar strategy with pegfilgrastim candidate to treat neutropenia